Inventiva announces trading resumption of its ordinary shares on Euronext Paris




Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company“), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH“), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). 

Trading of the ordinary shares of the Company was halted, at the Company’s request, on November 13, 2025, from 9:00 a.m. (CET), in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares, each representing one new ordinary share of the Company with a nominal value of €0.01 (the “Offering“), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com    

Contacts 

Important Notice

This press release contains certain forward-looking statements with respect to the proposed trading halt. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.

Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Disclaimers

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

France

The securities offered as part of the Offering have not been and will not be offered or sold to the public in France (except for public offerings defined in Article L.411-2 1° of the French Monetary and Financial Code).

The securities offered as part of the Offering may only be offered or sold in France pursuant to Article L. 411-2 1° of the French Monetary and Financial Code to “qualified investors” (investisseurs qualifiés) (as such term is defined in Article 2(e) of Prospectus Regulation) acting for their own account, and in accordance with Articles L. 411-1, L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code.

This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.

European Economic Area

In relation to each Member State of the European Economic Area (each, a “Member State”) no offer to the public of securities may be made in that Member State other than:

• to any legal entity which is a ‘‘qualified investor’’ as defined in the Prospectus Regulation;
• to fewer than 150 natural or legal persons (other than a qualified investor as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the placement agents for any such offer; or
• in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of securities shall require us or any placement agent to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the placement agents and the Company that it is a ‘‘qualified investor’’ as defined in the Prospectus Regulation.

For the purposes of this provision, the expression an “offer to the public” in relation to any securities in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any ordinary shares.

United Kingdom

This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order“), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issuance or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons“). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Attachment

• Inventiva – PR – Resumption of Trading Press Release – EN -11 13 2025

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers




Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Geleen, November 13^th, 2025.

Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced top line results from its phase 1 study evaluating the safety, tolerability & pharmacokinetics of a 120-hour intravenous (IV) continuous infusion with its lead compound M6229. The study met its primary objectives, showing  favorable safety and tolerability in healthy volunteers. This study also confirmed that M6229, shows a predictable pharmacokinetic behavior for a 120-h continuous infusion.

The data from this healthy volunteer study, together with previously obtained results from a study in intensive care sepsis patients, provide sufficient basis for the design and execution of a Phase 2 study in sepsis patients to select the preferred dosing strategy in these patients. Matisse will submit regulatory dossiers for approval of the study in the US, Europe and Asia. 

The Matisse sponsored single-blind, randomized, placebo-controlled study has been executed and managed by Charité Research Organisation located in Berlin, Germany.

 “We believe that a prolonged infusion duration could offer an effective solution for irreversibly stopping the harmful inflammatory responses that occur in sepsis patients. With these data we take a very important step in applying this extended  infusion in our phase 2 study to treat sepsis patients, which is currently in preparation”, says Kees Groen, Chief Development Officer of Matisse Pharmaceuticals.

In Matisse’s first and successful human clinical trial in severely ill sepsis patients, finalized in 2024, a 6 hour continuous IV infusion was applied. The study showed a favorable safety and tolerability profile as well as close to dose-proportional pharmacokinetics of IV administered M6229 in critically ill patients with sepsis. The study also showed beneficial pharmacodynamic effects on histones, CRP levels and other inflammatory biomarkers. A decrease in SOFA (Sequential Organ Failure Assessment) score was found for 70% of the patients following the three days after the infusion day. 

About Matisse Pharmaceuticals
Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. Matisse is dedicated to develop a product portfolio of safe and innovative therapies for disease indications characterized by elevated levels of circulating cytotoxic histones, such as in sepsis.

Matisse’s platform technology M6229 is based on the discovery that in patients suffering from sepsis, proteins called histones are released into the blood stream by the innate immune system which are toxic to cell membranes leading to cell death and release of additional histones. Due to this self-enforcing cascade, septic patients threaten to die from organ failure. The highly negatively charged M6229 preferentially binds to the positively charged extracellular histones and inhibits the self-enforcing cascade of increasing histone levels, thereby preventing further organ damage and death.

About sepsis

According to the WHO, sepsis is one of the leading causes of death worldwide. Currently, there is no effective treatment against sepsis approved by regulatory authorities. From the 49 million patients globally suffering from sepsis every year, more than 20% die. Approximately 40% of the sepsis cases are children under the age of 5, with close to 3 million children not surviving sepsis. According to a study by Buchman et al. (2020), published in the Journal of Critical Care Medicine, sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone.

For more information, please contact:

Marcel Jacobs, CEO
(T) +31 6 575 27 541
(E) m.jacobs@matissepharmaceuticals.com
(W) www.matissepharmaceuticals.com

Attachment

• HV Study press release picture

GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector




GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector

GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector

Évry-Courcouronnes, France, November 16th, 2025 – GenoSafe, the French Contract Research Organization (CRO) specialized in the characterization and evaluation of advanced therapy medicinal products (ATMPs), today inaugurates its new 1,200 m² laboratories at the Genopole biocluster in Évry-Courcouronnes, designed and equipped in accordance with Good Manufacturing Practices (GMP).

These new facilities strengthen GenoSafe’s ability to support its partners throughout the entire development cycle, from the laboratory to commercialization, while ensuring the highest standards for quality control, safety, and efficacy of medicines such as gene and cell therapy drugs, innovative vaccines, and DNA/RNA-based therapies.

Enhanced analytical capabilities to meet international standards

Thanks to these laboratories, GenoSafe can provide even more effective support to its partners – biotech companies, the pharmaceutical industry, laboratories, and institutions – in the design, validation, and execution of analytical methods required for the control and release of gene and cell therapy products. The new site also allows GenoSafe to expand its services into a broader range of advanced therapies, including therapeutic vaccines, RNA-based products, monoclonal antibodies, and other innovative therapies. Recruitment will be initiated in 2026 as the facilities become fully operational.

“These new laboratories reflect our ambition to provide a scientific and regulatory environment that meets the highest international standards for advanced therapy products. It marks a new milestone in GenoSafe’s growth and in the development of the French biotherapy ecosystem,” said Serge Braun, President of GenoSafe.

A French expertise with global reach

Founded in 2003 by Généthon and AFM-Téléthon, GenoSafe operates within Genopole, France’s leading biocluster dedicated to biotechnology and life sciences. The company supports every stage of innovative drug development, from preclinical studies to market authorization, across all analytical domains:

• Preclinical and clinical studies
• Quality control and release testing
• Regulatory support and analytical validation (in compliance with GLP, GMP, GCP standards)

With around 50 employees and more than 70% of its business conducted internationally (including 40% in the United States), GenoSafe collaborates with clients in over 15 countries, has participated in over 90 preclinical and clinical studies, and contributed to major European projects such as CureCN, UshTher, Net4CGD, Target-AMD, and ARDAT.

At GenoSafe, we combine scientific excellence and agility to deliver tailor-made analytical solutions, designed and performed in our own laboratories. From biotech start-ups to global leaders, we guide each partner toward successful development,”
said Alain Lamproye, CEO of GenoSafe.

Strong roots within the Évry and Genopole ecosystem

The inauguration took place in the presence of Stéphane Beaudet, Mayor of Évry-Courcouronnes and President of Genopole, along with representatives from AFM-Telethon and Genethon, long-standing partners of the company.

“GenoSafe’s expansion is excellent news for Genopole and for the entire region. It confirms Évry-Courcouronnes’ leading role in health innovation and in the development of tomorrow’s therapies,” said Stéphane Beaudet, Mayor of Évry-Courcouronnes and President of Genopole.

About GenoSafe

GenoSafe is a French analytical CRO specialized in advanced therapy medicinal products, with recognized expertise in gene and cell therapies. The company provides analytical development, validation, and quality control testing services, all performed in compliance with international regulatory standards (GLP, GMP, GCP).

Founded in 2003 by Genethon and AFM-Telethon, GenoSafe supports innovative projects throughout all development phases and contributes to high-impact scientific and societal programs worldwide.

With a workforce of about 50, GenoSafe provides support to around 50 active clients worldwide each year.

www.genosafe.com

Media Contact

Marie Puvieux, press officer, ATCG Partners

+33 6 10 54 36 72

presse@atcg-partners.com

Attachment

• PR in English

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers




Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Geleen, November 13^th, 2025.

Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced top line results from its phase 1 study evaluating the safety, tolerability & pharmacokinetics of a 120-hour intravenous (IV) continuous infusion with its lead compound M6229. The study met its primary objectives, showing  favorable safety and tolerability in healthy volunteers. This study also confirmed that M6229, shows a predictable pharmacokinetic behavior for a 120-h continuous infusion.

The data from this healthy volunteer study, together with previously obtained results from a study in intensive care sepsis patients, provide sufficient basis for the design and execution of a Phase 2 study in sepsis patients to select the preferred dosing strategy in these patients. Matisse will submit regulatory dossiers for approval of the study in the US, Europe and Asia. 

The Matisse sponsored single-blind, randomized, placebo-controlled study has been executed and managed by Charité Research Organisation located in Berlin, Germany.

 “We believe that a prolonged infusion duration could offer an effective solution for irreversibly stopping the harmful inflammatory responses that occur in sepsis patients. With these data we take a very important step in applying this extended  infusion in our phase 2 study to treat sepsis patients, which is currently in preparation”, says Kees Groen, Chief Development Officer of Matisse Pharmaceuticals.

In Matisse’s first and successful human clinical trial in severely ill sepsis patients, finalized in 2024, a 6 hour continuous IV infusion was applied. The study showed a favorable safety and tolerability profile as well as close to dose-proportional pharmacokinetics of IV administered M6229 in critically ill patients with sepsis. The study also showed beneficial pharmacodynamic effects on histones, CRP levels and other inflammatory biomarkers. A decrease in SOFA (Sequential Organ Failure Assessment) score was found for 70% of the patients following the three days after the infusion day. 

About Matisse Pharmaceuticals
Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. Matisse is dedicated to develop a product portfolio of safe and innovative therapies for disease indications characterized by elevated levels of circulating cytotoxic histones, such as in sepsis.

Matisse’s platform technology M6229 is based on the discovery that in patients suffering from sepsis, proteins called histones are released into the blood stream by the innate immune system which are toxic to cell membranes leading to cell death and release of additional histones. Due to this self-enforcing cascade, septic patients threaten to die from organ failure. The highly negatively charged M6229 preferentially binds to the positively charged extracellular histones and inhibits the self-enforcing cascade of increasing histone levels, thereby preventing further organ damage and death.

About sepsis

According to the WHO, sepsis is one of the leading causes of death worldwide. Currently, there is no effective treatment against sepsis approved by regulatory authorities. From the 49 million patients globally suffering from sepsis every year, more than 20% die. Approximately 40% of the sepsis cases are children under the age of 5, with close to 3 million children not surviving sepsis. According to a study by Buchman et al. (2020), published in the Journal of Critical Care Medicine, sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone.

For more information, please contact:

Marcel Jacobs, CEO
(T) +31 6 575 27 541
(E) m.jacobs@matissepharmaceuticals.com
(W) www.matissepharmaceuticals.com

Attachment

• HV Study press release picture

Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic




Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic

New funding brings total capital raised to $135 million 

Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source

Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins

BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, today announced the close of a $65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company (“Lilly”), as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners.

The funding will advance Gate’s lead molecular gate programs into the clinic and support the continued expansion of its differentiated molecular gate programs across inflammation and other therapeutic areas.

In connection with the financing, Vanessa Carle, Ph.D., Principal at Forbion, will join Gate’s Board of Directors, contributing extensive experience in building and scaling innovative therapeutics companies across Europe and the United States.

“Gate represents a rare opportunity to invest in a truly differentiated therapeutic modality with significant advantages over existing treatments,” said Dr. Carle. “The Company’s molecular gate platform addresses high-value, clinically validated targets across multiple therapeutic areas with an oral small molecule approach, which is something that has eluded the field until now. With its experienced team and differentiated platform, Gate is uniquely positioned to disrupt treatment paradigms in inflammatory and neurological diseases, potentially unlocking significant value across underserved markets.”

Gate’s portfolio of molecular gates targets high value, well-validated proteins in inflammatory and neurological diseases, offering the convenience of a pill and the potential for superior efficacy through a novel mechanism of action. By eliminating inflammatory proteins like cytokines inside the cell before secretion, Gate’s approach may be more effective than treatments that act only after these proteins enter circulation. In the brain, molecular gates that easily cross the blood-brain barrier can address disease-causing proteins that traditional biologics cannot.

“Molecular gates have the potential to be transformative drugs for diseases where current treatments fall short,” said Jordi Mata-Fink, Ph.D., Co-Founder and CEO of Gate Bioscience. “Because the mechanism is so differentiated, we’ve been able to build a portfolio with low biology risk and best-in-class potential across multiple therapeutic areas. We’re also seeing the fruits of our platform investment, which has matured into a true drug discovery engine that allows us to make selective molecular gates repeatedly and efficiently, both for our own pipeline and for our biopharma partners. We are grateful for the support of Forbion, Lilly, and our existing investors, which will help us test the first molecular gate medicines in the clinic and continue to expand our portfolio.”

The proceeds from the Series B will advance Gate’s lead programs through IND-enabling studies and Phase 1 clinical trials to generate clinical proof-of-concept data. Additionally, the funding will support the discovery of molecular gates to target additional high value proteins and strengthen Gate’s discovery platform to enhance speed and efficiency.

About Molecular Gates

Molecular gates are orally available small molecule drugs that eliminate a target protein potently and selectively by blocking the protein’s progress through the secretory channel Sec61, leading to its degradation. Among the approximately 4,000 targets of molecular gates are many high-value targets in the areas of immunology, neuroscience, and other diseases, which currently have no therapies or require injectables to eliminate the target protein.

About Gate Bioscience

Gate Bioscience is a biotechnology company developing molecular gates, a new class of small molecule medicines that eliminate disease-causing proteins at their source. Gate’s proprietary Molecular Gate Discovery Platform enables the rapid and repeatable discovery of selective molecular gates against high-value targets across inflammatory and neurological diseases. The platform integrates a privileged library of molecular gate compounds, a suite of secretion-focused assays and technologies, and deep expertise in the biology of the secretory pathway. For more information, visit www.gatebio.com.

About Forbion

Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.

Media Contact:
Carly Scaduto
THRUST Strategic Communications
carly@thrustsc.com 

GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector




GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector

GenoSafe strengthens its leadership in analytical expertise with the opening of new GMP-compliant laboratories to support the advanced therapies sector

Évry-Courcouronnes, France, November 16th, 2025 – GenoSafe, the French Contract Research Organization (CRO) specialized in the characterization and evaluation of advanced therapy medicinal products (ATMPs), today inaugurates its new 1,200 m² laboratories at the Genopole biocluster in Évry-Courcouronnes, designed and equipped in accordance with Good Manufacturing Practices (GMP).

These new facilities strengthen GenoSafe’s ability to support its partners throughout the entire development cycle, from the laboratory to commercialization, while ensuring the highest standards for quality control, safety, and efficacy of medicines such as gene and cell therapy drugs, innovative vaccines, and DNA/RNA-based therapies.

Enhanced analytical capabilities to meet international standards

Thanks to these laboratories, GenoSafe can provide even more effective support to its partners – biotech companies, the pharmaceutical industry, laboratories, and institutions – in the design, validation, and execution of analytical methods required for the control and release of gene and cell therapy products. The new site also allows GenoSafe to expand its services into a broader range of advanced therapies, including therapeutic vaccines, RNA-based products, monoclonal antibodies, and other innovative therapies. Recruitment will be initiated in 2026 as the facilities become fully operational.

“These new laboratories reflect our ambition to provide a scientific and regulatory environment that meets the highest international standards for advanced therapy products. It marks a new milestone in GenoSafe’s growth and in the development of the French biotherapy ecosystem,” said Serge Braun, President of GenoSafe.

A French expertise with global reach

Founded in 2003 by Généthon and AFM-Téléthon, GenoSafe operates within Genopole, France’s leading biocluster dedicated to biotechnology and life sciences. The company supports every stage of innovative drug development, from preclinical studies to market authorization, across all analytical domains:

• Preclinical and clinical studies
• Quality control and release testing
• Regulatory support and analytical validation (in compliance with GLP, GMP, GCP standards)

With around 50 employees and more than 70% of its business conducted internationally (including 40% in the United States), GenoSafe collaborates with clients in over 15 countries, has participated in over 90 preclinical and clinical studies, and contributed to major European projects such as CureCN, UshTher, Net4CGD, Target-AMD, and ARDAT.

At GenoSafe, we combine scientific excellence and agility to deliver tailor-made analytical solutions, designed and performed in our own laboratories. From biotech start-ups to global leaders, we guide each partner toward successful development,”
said Alain Lamproye, CEO of GenoSafe.

Strong roots within the Évry and Genopole ecosystem

The inauguration took place in the presence of Stéphane Beaudet, Mayor of Évry-Courcouronnes and President of Genopole, along with representatives from AFM-Telethon and Genethon, long-standing partners of the company.

“GenoSafe’s expansion is excellent news for Genopole and for the entire region. It confirms Évry-Courcouronnes’ leading role in health innovation and in the development of tomorrow’s therapies,” said Stéphane Beaudet, Mayor of Évry-Courcouronnes and President of Genopole.

About GenoSafe

GenoSafe is a French analytical CRO specialized in advanced therapy medicinal products, with recognized expertise in gene and cell therapies. The company provides analytical development, validation, and quality control testing services, all performed in compliance with international regulatory standards (GLP, GMP, GCP).

Founded in 2003 by Genethon and AFM-Telethon, GenoSafe supports innovative projects throughout all development phases and contributes to high-impact scientific and societal programs worldwide.

With a workforce of about 50, GenoSafe provides support to around 50 active clients worldwide each year.

www.genosafe.com

Media Contact

Marie Puvieux, press officer, ATCG Partners

+33 6 10 54 36 72

presse@atcg-partners.com

Attachment

• PR in English

Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic




Gate Bioscience Announces $65 Million Oversubscribed Series B Financing to Advance Oral Molecular Gate Medicines into the Clinic

New funding brings total capital raised to $135 million 

Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source

Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins

BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, today announced the close of a $65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company (“Lilly”), as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners.

The funding will advance Gate’s lead molecular gate programs into the clinic and support the continued expansion of its differentiated molecular gate programs across inflammation and other therapeutic areas.

In connection with the financing, Vanessa Carle, Ph.D., Principal at Forbion, will join Gate’s Board of Directors, contributing extensive experience in building and scaling innovative therapeutics companies across Europe and the United States.

“Gate represents a rare opportunity to invest in a truly differentiated therapeutic modality with significant advantages over existing treatments,” said Dr. Carle. “The Company’s molecular gate platform addresses high-value, clinically validated targets across multiple therapeutic areas with an oral small molecule approach, which is something that has eluded the field until now. With its experienced team and differentiated platform, Gate is uniquely positioned to disrupt treatment paradigms in inflammatory and neurological diseases, potentially unlocking significant value across underserved markets.”

Gate’s portfolio of molecular gates targets high value, well-validated proteins in inflammatory and neurological diseases, offering the convenience of a pill and the potential for superior efficacy through a novel mechanism of action. By eliminating inflammatory proteins like cytokines inside the cell before secretion, Gate’s approach may be more effective than treatments that act only after these proteins enter circulation. In the brain, molecular gates that easily cross the blood-brain barrier can address disease-causing proteins that traditional biologics cannot.

“Molecular gates have the potential to be transformative drugs for diseases where current treatments fall short,” said Jordi Mata-Fink, Ph.D., Co-Founder and CEO of Gate Bioscience. “Because the mechanism is so differentiated, we’ve been able to build a portfolio with low biology risk and best-in-class potential across multiple therapeutic areas. We’re also seeing the fruits of our platform investment, which has matured into a true drug discovery engine that allows us to make selective molecular gates repeatedly and efficiently, both for our own pipeline and for our biopharma partners. We are grateful for the support of Forbion, Lilly, and our existing investors, which will help us test the first molecular gate medicines in the clinic and continue to expand our portfolio.”

The proceeds from the Series B will advance Gate’s lead programs through IND-enabling studies and Phase 1 clinical trials to generate clinical proof-of-concept data. Additionally, the funding will support the discovery of molecular gates to target additional high value proteins and strengthen Gate’s discovery platform to enhance speed and efficiency.

About Molecular Gates

Molecular gates are orally available small molecule drugs that eliminate a target protein potently and selectively by blocking the protein’s progress through the secretory channel Sec61, leading to its degradation. Among the approximately 4,000 targets of molecular gates are many high-value targets in the areas of immunology, neuroscience, and other diseases, which currently have no therapies or require injectables to eliminate the target protein.

About Gate Bioscience

Gate Bioscience is a biotechnology company developing molecular gates, a new class of small molecule medicines that eliminate disease-causing proteins at their source. Gate’s proprietary Molecular Gate Discovery Platform enables the rapid and repeatable discovery of selective molecular gates against high-value targets across inflammatory and neurological diseases. The platform integrates a privileged library of molecular gate compounds, a suite of secretion-focused assays and technologies, and deep expertise in the biology of the secretory pathway. For more information, visit www.gatebio.com.

About Forbion

Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.

Media Contact:
Carly Scaduto
THRUST Strategic Communications
carly@thrustsc.com 

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference




CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT.

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY^® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial




MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio

Trial Enrollment Ongoing

MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to evaluate the performance of the Company’s EPIEFFECT^® product in comparison to standard of care (“SOC”) wound treatment.

The study, entitled “Evaluation of lyophilized human amnion/chorion membrane (“LHACM”) in the management of nonhealing diabetic foot ulcers: an interim analysis of the CAMPAIGN trial,” was recently published in the International Journal of Tissue Repair. Enrollment for CAMPAIGN is still ongoing; however, advanced predictive models indicate superiority of MIMEDX’s EPIEFFECT over SOC based upon 71 enrolled patients. The Company also presented at the Tissue Research Evidence Summit (“TRES”) in New Orleans, La. on October 30, 2025 with an expanded 88 patient sample set, further widening the gap between EPIEFFECT and SOC.

In the CAMPAIGN study design, success was defined as a posterior probability > 90%, and the interim results demonstrated the posterior probability that LHACM was superior to standard of care was 98.5%.

“Since its launch in 2023, EPIEFFECT has garnered significant praise for its clinical efficacy and utility. Until now, this has been based solely upon real-world evidence. We are, therefore, extremely pleased with the favorable results being demonstrated in this latest RCT. Thus far, EPIEFFECT recipients outperformed those treated with SOC, and we are optimistic that this study will have a successful read out upon completion,” stated Joseph H. Capper, MIMEDX Chief Executive Officer.

“MIMEDX’s ongoing commitment to demonstrating the scientific and clinical efficacy of our product portfolio once again shines through in this interim analysis. We believe the results present a compelling case for Medicare and commercial insurance coverage for this product, particularly in light of pending Local Coverage Determination (“LCD”) implementations, scheduled for January 1, 2026. To that end, we believe our EPIEFFECT study results presented at TRES stood out as having met the current criteria for inclusion under the LCDs,” concluded Mr. Capper.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.




Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.

KELOWNA, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce that its wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner.

This milestone represents a step in Doseology’s operational evolution—establishing the commercial infrastructure, manufacturing capacity, and regulatory foundation required to support the Company’s transition from development of its oral stimulant pouches to full market readiness.

“This is much more than a manufacturing agreement, it’s a defining moment as it enables Doseology to move from R&D to commercial deployment,” said Tim Corkum, President & COO of Doseology. “Through Doseology USA Inc., we’ve secured an American partner that delivers the scale, quality, and integrity we require as we prepare to enter the oral stimulant pouch market.”

Extensive Diligence Across North America

Doseology’s leadership conducted on-site reviews, operational assessments, and compliance audits across numerous facilities throughout the United States and Canada.

After rigorous evaluation, the Company selected a partner recognized for:

• Certified & Compliant Production: FDA-registered, GMP-certified, and ISO 9001:2015-approved facility ensuring pharmaceutical-grade quality and safety.
• Turnkey Manufacturing Expertise: End-to-end solutions spanning formulation, ingredient sourcing, blending, pouch filling, packaging, and logistics.
• Oral Pouch Specialization: Precision control across nicotine, caffeine, and nootropic pouch formats—customizable by dosage, moisture, and flavour.
• Rigorous Quality & Regulatory Systems: Built-in QA, traceability, and labeling practices fully aligned with FDA and ISO standards.
• Scalable, Low-Risk Partnership Model: Flexible production volumes that accommodate early pilot runs, regional launches, and high-volume commercial production designed to minimize capital investment while accelerating go-to-market.

“Our diligence process was deliberate and comprehensive,” added Corkum. “We wanted an American manufacturing partnership that reflects our core values—integrity, quality, and accountability. As we enter the market, this ensures Doseology’s products are built on a foundation of trusted North American craftsmanship and scientific precision.”

A Defining Milestone for Shareholders

The signing of this manufacturing agreement by Doseology USA Inc. marks a key inflection point in Doseology’s investment and commercialization cycle, demonstrating that the Company has now established the operational backbone to execute its strategy and deliver measurable progress in the oral stimulant pouch market.

“This step validates our readiness to scale,” said Corkum. “We’ve secured the right partner, the right structure, and the right systems to move confidently into the next stage of our growth. For shareholders, this milestone signals tangible execution and a disciplined pathway toward value creation.”

“This agreement represents a pivotal step in Doseology’s ability to commercialize efficiently and responsibly,” added Patrick Sills, Strategic Commercialization Advisor to Doseology. “Having worked closely with global category leaders such as Swedish Match, the parent company behind ZYN, I’ve seen firsthand how disciplined manufacturing, compliance, and scalability form the bedrock of long-term success. Doseology’s approach—combining science-driven product development with thoroughly vetted North American infrastructure—built on the same strategic foundation that defined today’s market leading oral stimulant brands. This partnership validates the Company’s commitment to execution, quality, and shareholder value.”

Building for Market Leadership

Led by executives with deep experience in regulated Big Tobacco, CPG, Nutraceuticals, and Corporate Finance, Doseology continues to build a North American infrastructure network designed to support innovation, compliance, and performance at scale.

The establishment of Doseology USA Inc. further strengthens the Company’s operational presence in the United States and underscores its commitment to American-made production integrity, sustainable growth, and long-term shareholder value.

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology is a biotech innovation company, engineering precision‑formulated oral stimulants that are designed to optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we’re pioneering next‑gen performance solutions designed to empower peak performance.

Website: www.doseology.com

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

Media Contact

Chris Jackson
Email: hello@doseology.com
Phone: 604.908.3095